Heterocyclic compounds can be divided into two categories: alicyclic heterocycles and aromatic heterocycles. Compounds whose heterocycles in the molecular skeleton cannot reflect aromaticity are called alicyclic heterocyclic compounds. Compound: 136725-55-8, is researched, Molecular C4H9ClFN, about Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors, the main research direction is DYRK inhibitor ligand efficient.Reference of (R)-(-)-3-Fluoropyrrolidine Hydrochloride.
Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) regulates the proliferation and differentiation of neuronal progenitor cells during brain development. Consequently, DYRK1A has attracted interest as a target for the treatment of neurodegenerative diseases, including Alzheimer′s disease (AD) and Down′s syndrome. Recently, the inhibition of DYRK1A has been investigated as a potential treatment for diabetes, while DYRK1A′s role as a mediator in the cell cycle has garnered interest in oncol. indications. Structure-activity relationship (SAR) anal. in combination with high-resolution X-ray crystallog. leads to a series of pyrazolo[1,5-b]pyridazine inhibitors with excellent ligand efficiencies, good physicochem. properties, and a high degree of selectivity over the kinome. Compound 11 (I) exhibited good permeability and cellular activity without P-glycoprotein liability, extending the utility of 11 in an in vivo setting. These pyrazolo[1,5-b]pyridazines are a viable lead series in the discovery of new therapies for the treatment of diseases linked to DYRK1A function.
In some applications, this compound(136725-55-8)Reference of (R)-(-)-3-Fluoropyrrolidine Hydrochloride is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.
Reference:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem